Researchers have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers. The results show ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $38.25, with a +1.38% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 1.47%.